Related Experiment Video
Updated: Jul 19, 2026
10:19
Induction of an Isoelectric Brain State to Investigate the Impact of Endogenous Synaptic Activity on Neuronal Excitability In Vivo
Published on: March 31, 2016
[Prevention of myoclonus after etomidate using a priming dose]
Y Aissaoui1, L Belyamani, A El Wali
1Service d'anesthésiologie, département d'anesthésie réanimation et urgences, hôpital militaire d'instruction des armées Mohammed-V, CHU de Rabat, Morocco. younes.aissaoui@hotmail.com
Annales Francaises D'Anesthesie Et De Reanimation
|September 29, 2006
Summary
Pretreating patients with a low dose of etomidate effectively reduces etomidate-induced myoclonus during anesthesia induction. This priming strategy significantly lowers the incidence of involuntary muscle movements without adverse effects.
Area of Science:
- Anesthesiology
- Pharmacology
Context:
- Etomidate is a common anesthetic agent.
- Etomidate administration can cause myoclonus, an involuntary muscle movement.
- Minimizing side effects of anesthetic agents is crucial for patient safety.
Purpose:
- To evaluate the efficacy of a low-dose etomidate priming strategy in preventing etomidate-induced myoclonus.
- To assess the incidence and severity of myoclonus following etomidate induction with and without pretreatment.
Summary:
- A prospective, randomized, double-blind study involved 46 patients undergoing elective surgery.
- The priming group received 0.03 mg/kg etomidate 60 seconds before induction, while the control group received a placebo.
- Myoclonus occurred in 87% of the control group versus 26% of the priming group (P<0.001).
Impact:
- Pretreatment with low-dose etomidate is a safe and effective method to reduce etomidate-induced myoclonus.
- This finding can improve patient comfort and anesthetic management.
- The study supports the use of etomidate priming to mitigate a common side effect.
Related Concept Videos
01:24Parenteral Anesthetics: Overview
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:28Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...